Related Experiment Video

Updated: Aug 13, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

[Effect of prestarium in patients with chronic heart failure]

T B Abashidze, R M Lortkipanidze

    Georgian Medical News
    |January 31, 2006
    PubMed

    Insights

    Prestarium, an angiotensin-converting enzyme inhibitor, improved chronic heart failure (CHF) patients' functional class and exercise capacity. The drug also enhanced central hemodynamics, improving left ventricular (LV) function and volumes.

    Area of Science:

    • Cardiology
    • Pharmacology

    Context:

    • Chronic heart failure (CHF) progression is significantly influenced by the renin-angiotensin system (RAS), particularly angiotensin-II.
    • Angiotensin-II mediates detrimental effects including vasoconstriction, elevated blood pressure, cardiac hypertrophy, and fibrosis, impacting patient prognosis and quality of life.

    Purpose:

    • To evaluate the efficacy of Prestarium, an angiotensin-converting enzyme (ACE) inhibitor, in managing patients with chronic heart failure (CHF).

    Summary:

    • Prestarium treatment led to significant improvements in the functional class (FC) and increased the 6-minute walking distance in CHF patients.
    • The study observed consistent improvements in central hemodynamic parameters, including a statistically significant enhancement of end-systolic volume and left ventricular (LV) ejection fraction within 3 months.
    • Patients reported a slight improvement in their quality of life.

    Impact:

    • Prestarium demonstrates beneficial effects on the clinical status of CHF patients.
    • The medication positively influences left ventricular (LV) volumes and contractile capability.
    • ACE inhibition with Prestarium offers a therapeutic strategy to improve outcomes in chronic heart failure.

    Related Concept Videos

    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    Heart Failure IV: Classification and Diagnostic Evaluation01:30

    Heart Failure IV: Classification and Diagnostic Evaluation

    Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...